Cargando…

Dynamic and static circulating cancer microRNA biomarkers – a validation study

For cancers and other pathologies, early diagnosis remains the most promising path to survival. Profiling of longitudinal cohorts facilitates insights into trajectories of biomarkers. We measured microRNA expression in 240 serum samples from patients with colon, lung, and breast cancer and from canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu-Halima, Masood, Keller, Andreas, Becker, Lea Simone, Fischer, Ulrike, Engel, Annika, Ludwig, Nicole, Kern, Fabian, Rounge, Trine B., Langseth, Hilde, Meese, Eckart, Keller, Verena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754110/
https://www.ncbi.nlm.nih.gov/pubmed/36511578
http://dx.doi.org/10.1080/15476286.2022.2154470
_version_ 1784851115036114944
author Abu-Halima, Masood
Keller, Andreas
Becker, Lea Simone
Fischer, Ulrike
Engel, Annika
Ludwig, Nicole
Kern, Fabian
Rounge, Trine B.
Langseth, Hilde
Meese, Eckart
Keller, Verena
author_facet Abu-Halima, Masood
Keller, Andreas
Becker, Lea Simone
Fischer, Ulrike
Engel, Annika
Ludwig, Nicole
Kern, Fabian
Rounge, Trine B.
Langseth, Hilde
Meese, Eckart
Keller, Verena
author_sort Abu-Halima, Masood
collection PubMed
description For cancers and other pathologies, early diagnosis remains the most promising path to survival. Profiling of longitudinal cohorts facilitates insights into trajectories of biomarkers. We measured microRNA expression in 240 serum samples from patients with colon, lung, and breast cancer and from cancer-free controls. Each patient provided at least two serum samples, one prior to diagnosis and one following diagnosis. The median time interval between the samples was 11.6 years. Using computational models, we evaluated the circulating profiles of 21 microRNAs. The analysis yielded two sets of biomarkers, static ones that show an absolute difference between certain cancer types and controls and dynamic ones where the level over time provided higher diagnostic information content. In the first group, miR-99a-5p stands out for all three cancer types. In the second group, miR-155-5p allows to predict lung cancers and colon cancers. Classification in samples from cancer and non-cancer patients using gradient boosted trees reached an average accuracy of 79.9%. The results suggest that individual change over time or an absolute value at one time point may predict a disease with high specificity and sensitivity.
format Online
Article
Text
id pubmed-9754110
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-97541102022-12-16 Dynamic and static circulating cancer microRNA biomarkers – a validation study Abu-Halima, Masood Keller, Andreas Becker, Lea Simone Fischer, Ulrike Engel, Annika Ludwig, Nicole Kern, Fabian Rounge, Trine B. Langseth, Hilde Meese, Eckart Keller, Verena RNA Biol Research Paper For cancers and other pathologies, early diagnosis remains the most promising path to survival. Profiling of longitudinal cohorts facilitates insights into trajectories of biomarkers. We measured microRNA expression in 240 serum samples from patients with colon, lung, and breast cancer and from cancer-free controls. Each patient provided at least two serum samples, one prior to diagnosis and one following diagnosis. The median time interval between the samples was 11.6 years. Using computational models, we evaluated the circulating profiles of 21 microRNAs. The analysis yielded two sets of biomarkers, static ones that show an absolute difference between certain cancer types and controls and dynamic ones where the level over time provided higher diagnostic information content. In the first group, miR-99a-5p stands out for all three cancer types. In the second group, miR-155-5p allows to predict lung cancers and colon cancers. Classification in samples from cancer and non-cancer patients using gradient boosted trees reached an average accuracy of 79.9%. The results suggest that individual change over time or an absolute value at one time point may predict a disease with high specificity and sensitivity. Taylor & Francis 2022-12-13 /pmc/articles/PMC9754110/ /pubmed/36511578 http://dx.doi.org/10.1080/15476286.2022.2154470 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Abu-Halima, Masood
Keller, Andreas
Becker, Lea Simone
Fischer, Ulrike
Engel, Annika
Ludwig, Nicole
Kern, Fabian
Rounge, Trine B.
Langseth, Hilde
Meese, Eckart
Keller, Verena
Dynamic and static circulating cancer microRNA biomarkers – a validation study
title Dynamic and static circulating cancer microRNA biomarkers – a validation study
title_full Dynamic and static circulating cancer microRNA biomarkers – a validation study
title_fullStr Dynamic and static circulating cancer microRNA biomarkers – a validation study
title_full_unstemmed Dynamic and static circulating cancer microRNA biomarkers – a validation study
title_short Dynamic and static circulating cancer microRNA biomarkers – a validation study
title_sort dynamic and static circulating cancer microrna biomarkers – a validation study
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754110/
https://www.ncbi.nlm.nih.gov/pubmed/36511578
http://dx.doi.org/10.1080/15476286.2022.2154470
work_keys_str_mv AT abuhalimamasood dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy
AT kellerandreas dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy
AT beckerleasimone dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy
AT fischerulrike dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy
AT engelannika dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy
AT ludwignicole dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy
AT kernfabian dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy
AT roungetrineb dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy
AT langsethhilde dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy
AT meeseeckart dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy
AT kellerverena dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy